Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

P&G Raises Full-Year Sales Forecast, Warns High Prices Ahead – $PG $DIA $INVO

By John F. Heerdink, Jr.

As per reports, Procter & Gamble Company (PG) raised its full-year sales forecast and plans to continue inflate prices despite a drop in sales volumes, as high commodity price pressure continue to rise. P&G’s sales volumes dropped 6% in its second quarter ended December 31, led by declines in the company’s grooming business, including brands like Gillette and Braun, and its fabric & home care division, which includes Tide, Ariel and Mr. Clean.

P&G net sales dropped 1% to $20.77 billion in the quarter, hurt by stronger dollar on overseas revenue but exceeded market expectations. The company’s earnings per share stood at $1.59, in line with market estimate. Organic sales in China declined 7% due to COVID lockdowns and weaker consumer confidence.

“None of us globally really understand what the recovery rate in China is going to be,” stated CEO Jon Moeller.

P&G’s high-end SK-II skincare brand, popular in Asia, witnessed COVID-related declines. The company expects fiscal 2023 total sales to range between flat to a 1% drop, compared with its previous forecast of a 1% to 3% fall. It maintained its annual earnings forecast of flat to a 4% rise.

The Procter & Gamble Company (PG), a Dow 30 component, supplies branded consumer packaged goods to consumers across the globe.  To learn more about Procter & Gamble (PG) and to continue to track its progress please visit the Vista Partners Procter & Gamble Coverage Page

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives. 

Stay Informed! Stay Competitive! Please join us at Vista Partners to receive our FREE email updates throughout the week and view our exclusive content and research.


Fertility rates have hit a record low in the United States. The latest US government fertility statistics come from 2019, and they estimate there were 58.2 births year per 1,000 women of childbearing age (defined by the CDC as women between ages 15 and 44).

If you have ever struggled with infertility issues, or know someone who has, you are probably well aware of how demoralizing it can be. Imagine for a moment spending thousands of dollars and months of intensive medical procedure only to end up empty handed, exhausted, sad, and defeated because after all of that time, work, and money, you still don’t have a baby. That’s an incredibly difficult situation, and it’s becoming more common each passing year. Likewise, the need for more effective, less invasive infertility treatment options is increasing with each passing year. This is the sole focus of medtech company INVO Bioscience (NASDAQ: INVO). Learn more by reading the following story that we published recently. 

INVO Bioscience (NASDAQ: $INVO), A Company Seeking To Address A Massively Underserved Fertility Market

(Read Original Story: P&G raises sales forecast on price hikes, sees volumes fall in Reuters)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us